# DESCRIPTION

## TECHNICAL FIELD

- introduce immunoassay platforms for cancer diagnosis

## BACKGROUND

- describe limitations of current cancer detection methods

## SUMMARY

- diagnose HCC using laminin gamma 2 monomer
- determine HCC risk using laminin gamma 2 monomer
- monitor HCC progression using laminin gamma 2 monomer
- diagnose HCC using laminin gamma 2 monomer and PIVKA-II
- determine HCC risk using laminin gamma 2 monomer and PIVKA-II
- monitor HCC progression using laminin gamma 2 monomer and PIVKA-II
- diagnose HCC using laminin gamma 2 monomer and AFP
- determine HCC risk using laminin gamma 2 monomer and AFP
- monitor HCC progression using laminin gamma 2 monomer and AFP
- diagnose HCC using laminin gamma 2 monomer, PIVKA-II, and AFP
- determine HCC risk using laminin gamma 2 monomer, PIVKA-II, and AFP
- monitor HCC progression using laminin gamma 2 monomer, PIVKA-II, and AFP
- provide kit for detecting HCC using laminin gamma 2 monomer
- provide kit for detecting HCC using laminin gamma 2 monomer and PIVKA-II
- provide kit for detecting HCC using laminin gamma 2 monomer and AFP
- provide kit for detecting HCC using laminin gamma 2 monomer, PIVKA-II, and AFP
- diagnose pancreatic cancer using laminin gamma 2 monomer
- determine pancreatic cancer risk using laminin gamma 2 monomer
- monitor pancreatic cancer progression using laminin gamma 2 monomer
- diagnose pancreatic cancer using laminin gamma 2 monomer and CEA
- determine pancreatic cancer risk using laminin gamma 2 monomer and CEA
- monitor pancreatic cancer progression using laminin gamma 2 monomer and CEA
- diagnose pancreatic cancer using laminin gamma 2 monomer and CA19-9
- determine pancreatic cancer risk using laminin gamma 2 monomer and CA19-9
- monitor pancreatic cancer progression using laminin gamma 2 monomer and CA19-9

## DETAILED DESCRIPTION

- introduce biomarkers for cancer
- specify biomarkers for hepatocellular carcinoma
- specify biomarkers for pancreatic cancer
- outline methods for diagnosis and prognosis

### 1. DEFINITIONS

- define technical terms
- introduce open-ended transitional phrases
- explain numeric ranges
- define area under curve (AUC)
- define cancer
- list types of cancer
- define component
- list components of a kit
- define control subject
- define control group
- define label and detectable label
- explain signal-producing substances
- list examples of labels
- define radioactive label
- define enzymatic label
- define chemiluminescent label
- define fluorescent label
- define thermometric label
- define immuno-polymerase chain reaction label
- introduce acridinium compound
- define acridinium-9-carboxamide
- describe methods for preparing acridinium 9-carboxamides
- define acridinium-9-carboxylate aryl ester
- describe methods for preparing acridinium 9-carboxylate aryl esters
- define TNM system for staging hepatocellular carcinoma
- explain T groups
- explain N groups
- explain M groups
- define stage I hepatocellular carcinoma
- define stage II hepatocellular carcinoma
- define stage IIIA hepatocellular carcinoma
- define stage IIIB hepatocellular carcinoma
- define stage IIIC hepatocellular carcinoma
- define stage IVA hepatocellular carcinoma
- define stage IVB hepatocellular carcinoma
- define liver fibrosis
- define neoplasia
- define normal control
- define benign pancreatic disease
- define early stage pancreatic cancer
- define late stage pancreatic cancer
- define stage 0 pancreatic cancer
- define stage I pancreatic cancer
- define stage II pancreatic cancer
- define stage III pancreatic cancer
- define stage IV pancreatic cancer
- define predetermined cutoff
- define pretreatment reagent
- define quality control reagents
- define risk assessment
- define sample
- define sensitivity
- define specificity
- define series of calibrating compositions
- define subject
- define treat
- define variant
- describe variant nucleic acid
- describe variant peptide or polypeptide
- describe variant protein
- describe hydrophobicity index
- describe hydrophilicity value
- describe post-translational modification
- describe substantially identical nucleic acid sequence
- describe substantially identical amino acid sequence
- provide examples of biological samples
- describe methods for collecting and handling samples
- describe optional pretreatment of samples
- describe use of archival tissues
- describe protein or nucleotide isolation and purification

### 2. METHOD OF DIAGNOSING A DISEASE USING LAMININ GAMMA 2 MONOMER

- introduce method of diagnosing disease
- describe obtaining sample from subject
- determine level of laminin gamma 2 monomer in sample
- compare level to reference level
- indicate disease presence or risk with level change
- describe increase in level as indication of disease
- introduce additional biomarkers
- describe determining level of additional biomarker
- compare level to reference level
- indicate disease presence or risk with level change
- describe increase in levels as indication of disease
- introduce laminin gamma 2 monomer
- describe structure and function of laminin gamma 2 monomer
- introduce additional biomarkers
- describe protein induced vitamin K antagonist-II (PIVKA-II)
- describe alpha fetal protein (AFP)
- describe carcinoembryonic antigen (CEA)
- describe carbohydrate antigen 19-9 (CA19-9)
- introduce combinations of biomarkers
- describe detecting levels of laminin gamma 2 monomer and additional biomarkers
- indicate disease presence or risk with level change
- describe detecting levels of laminin gamma 2 monomer and PIVKA-II
- describe detecting levels of laminin gamma 2 monomer and AFP
- describe detecting levels of laminin gamma 2 monomer, PIVKA-II, and AFP
- describe detecting levels of laminin gamma 2 monomer and CEA
- describe detecting levels of laminin gamma 2 monomer and CA19-9
- describe detecting levels of laminin gamma 2 monomer, CEA, and CA19-9
- introduce disease diagnosis
- describe diagnosing hepatocellular carcinoma (HCC)
- describe diagnosing pancreatic cancer
- describe disease stages
- introduce pancreatic cancer
- define pancreatic cancer types
- describe method of diagnosing pancreatic cancer
- determine laminin gamma 2 monomer level
- determine additional biomarker levels
- measure laminin gamma 2 monomer and additional biomarkers
- describe change in laminin gamma 2 monomer level
- describe change in additional biomarker levels
- diagnose pancreatic cancer stage
- describe immunoassay method
- quantify biomarker levels
- describe antibody types
- describe immunoassay steps
- measure laminin gamma 2 monomer level using immunoassay
- measure additional biomarker levels using immunoassay
- describe immunoassay types
- describe ELISA method
- describe immobilized antibodies
- describe assay strip preparation
- describe sandwich ELISA method
- describe capture and detection antibodies
- describe sandwich assay principle
- describe method of diagnosing disease using laminin gamma 2 monomer
- introduce sandwich assay format
- describe formation of first antibody-laminin gamma 2 monomer complex
- describe use of solid support
- describe incubation conditions
- describe formation of second antibody-laminin gamma 2 monomer complex
- describe use of detectable label
- introduce reference levels
- describe reference levels for laminin gamma 2 monomer
- describe reference levels for PIVKA-II
- describe reference levels for AFP
- describe reference levels for CEA
- describe reference levels for CA19-9
- define elevated, lowered, and altered levels
- describe typical or normal levels
- describe altered levels
- describe comparison to normal subjects
- describe reference levels in serum
- list specific reference levels for laminin gamma 2 monomer
- list specific reference levels for PIVKA-II
- list specific reference levels for AFP
- list specific reference levels for CEA
- list specific reference levels for CA19-9
- introduce Adaptive Index Model methodology
- introduce receiver operating curve analysis
- describe ROC analysis
- introduce quartile analysis
- describe software packages for statistical analysis

### 3. METHOD OF DETERMINING RISK OF DEVELOPING THE DISEASE

- obtain biological sample and measure laminin gamma 2 monomer level
- compare level to reference level and determine risk

### 4. METHOD OF MONITORING PROGRESSION OF THE DISEASE

- obtain first and second biological samples
- measure laminin gamma 2 monomer levels in both samples
- compare levels and determine disease progression
- measure additional biomarker levels in both samples
- compare additional biomarker levels and determine disease progression
- determine disease progression based on both biomarkers

### 5. KIT

- provide instructions for detecting laminin gamma 2 monomer and/or additional biomarkers
- include reagents for detecting laminin gamma 2 monomer and/or additional biomarkers
- include reference standard for laminin gamma 2 monomer and/or additional biomarkers
- include reagents for specifically binding to laminin gamma 2 monomer and/or additional biomarkers
- include reagents for quantifying laminin gamma 2 monomer and/or additional biomarkers
- include containers for reagents
- include instructions for assaying test sample
- include conjugate antibody for each capture antibody
- include calibrator or control
- include buffer or substrate solution
- include stop solution
- include all necessary components for performing assay
- include instructions for generating standard curve
- include antibodies with detectable labels
- include reagents for labeling antibodies or analytes
- include quality control components
- include sensitivity panel members
- include calibrators and positive controls
- include buffers and solutions for sample isolation and treatment
- include containers for holding or storing sample
- include instrument for assisting with obtaining test sample
- include acridinium compounds as detectable labels
- include source of hydrogen peroxide
- include solid phase
- include detectable label conjugated to antibody
- include components for assaying test sample for another analyte
- include components for use in automated or semi-automated systems

### 6. EXAMPLES

- introduce example 1
- describe methods and materials
- detail antibody and antigen preparation
- analyze tumor markers for HCC
- perform statistical analysis
- introduce example 2
- establish laminin gamma 2 monomer immunoassay
- describe fully automated chemiluminescent immunoassay
- generate polyclonal antibody directed against laminin gamma 2 monomer
- describe 2H2 monoclonal antibody
- generate recombinant laminin gamma 2 monomer
- detail immunoassay procedure
- introduce example 3
- detect laminin gamma 2 monomer in specimens
- describe specimens
- present results
- introduce example 4
- examine serum concentration of laminin gamma 2 monomer in HCC stages
- detail immunoassay procedure for HCC stages
- present results
- show serum concentration of laminin gamma 2 monomer
- compare to healthy donor, liver cirrhosis, and hepatitis specimens
- examine Ln-γ2 levels in patients with chronic liver disease and HCC
- generate ROC graph for Ln-γ2, AFP, and PIVKA-II
- calculate AUC for each marker
- determine optimal cutoff value for Ln-γ2
- examine Ln-γ2 levels in patients with HCC and chronic liver disease
- compare Ln-γ2 to AFP and PIVKA-II as markers for HCC
- examine positive rate of detecting HCC for Ln-γ2, AFP, and PIVKA-II
- show positive rate of detecting HCC for combinations of markers
- examine Ln-γ2 levels in patients with HCC and healthy volunteers
- compare Ln-γ2 to AFP and PIVKA-II as markers for HCC
- examine positive rate of detecting HCC for Ln-γ2, AFP, and PIVKA-II
- show positive rate of detecting HCC for combinations of markers
- examine Ln-γ2 levels in patients with HCC and chronic liver disease
- compare Ln-γ2 to AFP and PIVKA-II as markers for HCC
- examine positive rate of detecting HCC for Ln-γ2, AFP, and PIVKA-II
- show positive rate of detecting HCC for combinations of markers
- present example 6
- examine serum concentration of Ln-γ2 in stages III and IV of pancreatic cancer
- compare to pancreatitis and healthy donor specimens
- present example 7
- examine specificity and sensitivity of Ln-γ2 as a marker for pancreatic cancer
- compare to CEA and CA19-9 as markers for pancreatic cancer
- generate ROC graph for Ln-γ2, CEA, and CA19-9
- calculate AUC for each marker
- examine positive rate of detecting pancreatic cancer for Ln-γ2, CEA, and CA19-9
- show positive rate of detecting pancreatic cancer for combinations of markers
- conclude that Ln-γ2 is a marker for diagnosis of pancreatic cancer
- conclude that combinations of markers have higher positive rate of detecting pancreatic cancer
- summarize results of examples 5-7
- conclude that Ln-γ2 is a more accurate marker for HCC and pancreatic cancer
- conclude that Ln-γ2 has higher sensitivity and specificity than other markers

## 7. CLAUSES

- define method of diagnosing HCC
- add additional biomarker to method
- compare levels of biomarkers
- specify biomarkers to determine
- specify conditions for identifying HCC
- specify biological sample type
- specify serum sample
- detect laminin gamma 2 monomer with immunoassay
- detect PIVKA-II and AFP with immunoassay
- specify immunoassay type
- specify reference level of PIVKA-II and AFP
- specify reference level of laminin gamma 2 monomer
- specify cutoff level
- determine cutoff level
- specify reference level in calibrator
- define method of determining HCC risk
- add additional biomarker to method
- compare levels of biomarkers
- specify biomarkers to determine
- specify conditions for identifying HCC
- specify biological sample type
- specify serum sample
- detect laminin gamma 2 monomer with immunoassay
- detect PIVKA-II and AFP with immunoassay
- specify immunoassay type
- specify reference level of PIVKA-II and AFP
- specify reference level of laminin gamma 2 monomer
- specify cutoff level
- determine cutoff level
- specify reference level in calibrator
- define method of monitoring HCC progression
- add additional biomarker to method
- compare levels of biomarkers
- specify biomarkers to determine
- specify conditions for identifying HCC progression
- specify biological sample type
- specify serum sample
- detect laminin gamma 2 monomer with immunoassay
- detect PIVKA-II and AFP with immunoassay
- specify immunoassay type
- specify reference level of PIVKA-II and AFP
- specify reference level of laminin gamma 2 monomer
- specify cutoff level

